重组人促红细胞生成素联合蔗糖铁治疗肿瘤相关性贫血的临床疗效

Therapeutic effect of recombinant human erythropoietin combined with sucrose iron in the treatment of cancer-related anemia

目的研究重组人促红细胞生成素(rhEPO)联合蔗糖铁治疗肿瘤相关性贫血(CRA)的临床疗效。方法选取2017年6月至2018年6月我院收治的36例CRA患者,随机将患者分为蔗糖铁组与rhEPO组,每组18例。其中蔗糖铁组患者采取蔗糖铁治疗,rhEPO组患者采取rhEPO联合蔗糖铁治疗,比较治疗前后2组患者血红蛋白(Hb)、红细胞压积(Hct)、网织红细胞(Ret)水平的变化,临床疗效,不良反应。结果治疗总有效率rhEPO组为94.44%,高于蔗糖铁组的72.22%,差异有统计学意义(χ^(2)=4.433,P=0.035)。与治疗前相比,治疗后蔗糖铁组和rhEPO组患者的Hb、Hct和Ret水平均明显升高,差异均有统计学意义(蔗糖铁组t=42.848,P<0.001;t=24.674,P<0.001;t=25.796,P<0.001;rhEPO组t=35.990,P<0.001;t=26.889,P<0.001;t=71.451,P<0.001);rhEPO组治疗后的Hb、Hct、Ret水平均明显优于蔗糖铁组,差异均有统计学意义(t=7.348,P<0.001;t=11.338,P<0.001;t=63.065,P<0.001)。2组不良反应总发生率比较差异无统计学意义(χ^(2)=0.000,P=1.000)。结论rhEPO联合蔗糖铁能快速提高CRA患者Hb水平,改善肿瘤患者贫血症状,而且不增加不良反应发生风险。

Objective To study the clinical effect of recombinant human erythropoietin(rhEPO)combined with sucrose iron in the treatment of cancer-related anemia(CRA).Methods A total of 36 patients with CRA who were treated in our hospital from June 2017 to June 2018 were randomly divided into two groups,18 cases each.The sucrose iron group was treated with sucrose iron and the rhEPO group was treated with rhEPO plus sucros iroa.Hemoglobin(Hb),hematocrit(Hct)and reticulocyte(Ret)were compared before and after treatment,meanwhile,the efficacy and incidence of adverse reactions was compared between the two groups.Results The total effective rate of the rhEPO group was 94.44%,which was significantly better than that of the sucrose iron group(72.22%;χ^(2)=4.433,P=0.035);after treatment,the Hb,Hct and Ret of the 2 group were significantly higher than before treatment(the sucrose iron group:t=42.848,P<0.001;t=24.674,P<0.001;t=25.796,P<0.001;the rhEPO group:t=35.990,P<0.001;t=26.889,P<0.001;t=71.451,P<0.001).The Hb,Hct and Ret in the rhEPO group after treatment were significantly better than those in the sucrose iron group(t=7.348,P<0.001;t=11.338,P<0.001;t=63.065,P<0.001).There was not statistically significant in the total incidence of adverse reactions between the two groups(χ^(2)=0.000,P=1.000).Conclusion The application of rhEPO combined with sucrose iron in patients with CRA can rapidly improve Hb level,improve anemia symptoms of tumor patients,and do not increase the risk of adverse reactions.